News for Regeneron Pharmaceuticals Stock (REGN)

Impacted Investors Are Invited By The Schall Law Firm To Reach Out As They Start A Probe Into Allegations Against Regeneron Pharmaceuticals Inc

Accesswire • 07/03/24

Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD

Zacks Investment Research • 07/03/24

Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

GlobeNewsWire • 07/03/24

Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD

GlobeNewsWire • 07/03/24

The Schall Law Firm Initiates Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Invites Impacted Investors To Reach Out

Accesswire • 07/02/24

Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm

PRNewsWire • 07/02/24

Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug

Zacks Investment Research • 07/02/24

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

GlobeNewsWire • 06/30/24

The Schall Law Firm Begins Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Make Contact

Accesswire • 06/28/24

Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

GlobeNewsWire • 06/28/24

Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024

GlobeNewsWire • 06/27/24

3 Biotech Stocks That Could Make Your Grandchildren Rich

InvestorPlace • 06/27/24

Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM

GlobeNewsWire • 06/26/24

Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

GlobeNewsWire • 06/26/24

The Schall Law Firm Initiates Inquiry Into Allegations Against Regeneron Pharmaceuticals Inc And Urges Investors Who Have Incurred Losses To Establish Communication

Accesswire • 06/26/24

The Schall Law Firm Initiates Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Urges Impacted Investors To Reach Out

Accesswire • 06/25/24

Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs

Benzinga • 06/24/24

Ophthalmologists Favor Genentech's Vabysmo and Regeneron's Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints

GlobeNewsWire • 06/24/24

The Schall Law Firm Commences Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Urges Impacted Investors To Establish Communication

Accesswire • 06/23/24

The Schall Law Firm Starts Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Initiate Contact

Accesswire • 06/22/24

The Schall Law Firm Initiates Probe Into Allegations Against Regeneron Pharmaceuticals Inc And Urges Impacted Investors To Establish Communication

Accesswire • 06/21/24

The Schall Law Firm Begins Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Contact Them

Accesswire • 06/20/24

The Schall Law Firm Begins Investigation Into Claims Against Regeneron Pharmaceuticals Inc And Encourages Affected Investors To Connect

Accesswire • 06/18/24

Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?

Zacks Investment Research • 06/18/24

The Schall Law Firm Has Initiated A Probe Into Allegations Against Regeneron Pharmaceuticals Inc (NASDAQ:REGN) And Urges Investors Who Have Incurred Losses To Reach Out

Accesswire • 06/17/24